Open access peer-reviewed Edited Volume

Drug Repurposing

Farid A. Badria

Mansoura University


Drug Repurposing Drug Repositioning Therapeutic Drugs Drug-target Interactions New Disease Pathways Drug Rescue On-Target Repositioning New Uses Approved Drugs Investigational drugs

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Drug repositioning is a promising field in drug discovery that identifies new therapeutic opportunities for existing drugs. It can provide new treatment options to overcome cancer cell resistance or drug resistance in general. In this regard, old drugs seem to be ideal candidates for either reposition or combination therapy with known chemotherapeutic drugs. Despite the continuous research for treating cancer patients for example , chemotherapy and surgery are considered the main treatment options for many cancer patients worldwide. However, development of cancer cell resistance to chemotherapy remains a major obstacle for successful treatment and decreases sensitivity to different current chemotherapeutic drugs . Development of cancer cell resistance is attributed to different cellular mechanisms such as development of multidrug resistance (MDR). Therefore, there is no wonder that several research studies have been directed toward discovery of chemosensitizing agents among commonly available approved drugs that will not only increase sensitivity of cancer cells but will also decrease the applied doses of chemotherapeutic drugs and their associated side effects. Therefore, several researches have been directed to discover novel compounds that interfere with these efflux pumps such as P-glycoprotein and consequently enhance cancer cell sensitivity towards chemotherapeutic drugs. Recently, it has been proved that an old anti-malarial drug chloroquine showed to be a good candidate for interfering with MDR in several types of cancer. Moreover, quinine, which is a known and commercially available natural anti-malarial alkaloid has been reported for its efficacy as chemosensitizer in human leukemic cells.

This book will be a self-contained collection of scholarly papers targeting an audience of practicing researchers, academics, PhD students and other scientists. The contents of the book will be written by multiple authors and edited by experts in the field.

Publishing process

Book initiated and editor appointed

Date completed: December 6th 2019

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: February 25th 2020

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: May 15th 2020

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: July 14th 2020

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Farid A. Badria

Mansoura University

Professor Farid Badria, Ph.D. in Pharmacognosy (Microbial Transformation) from the Uni-versity of Mississippi, USA, with a B.Sc. in Pharmaceutical Sciences, and 2 Masters of Sci-ence in Pharmacognosy and Cell Biology from Mansoura University and the University of Minnesota. TWAS-Prize for "Public Understanding and Popularization of Science" (2013), World Intel-lectual Property Organization Gold Medal, 2011[the best Inventor in Egypt]; State Recogni-tion Outstanding Award in Medicine (Egyptian Academy of Science) 2001; Outstanding Arab Scholar, Kuwait (2000); Khawrazmi International Award, Iran (2000), are just to men-tion some of the awards he received. He’s also been a scholar of: the Arab Development Fund, Kuwait (2000); ICRO-UNESCO International, Chile (1999); UNESCO Biotechnology Fellowship, France (1994); Honorary Fellowship, University of Mississippi, USA (1987-90). Prof. Badria has submitted 44 patents to the Egyptian Academy of Sciences, of which 16 had been granted final certificates with intellectual protection for 20 years. With over 200 publications, 4 books, editor of 5 books, He continues to lead research projects on: developing new therapy for liver disorders, arthritis, skin disorders, and biomarkers for cancer. Prof. Farid Badria is actively involved in international collaboration as visiting Professor, Institut fur Physiologische Chemie, Abteilung Angewandte Moleku-larbiologie, Mainz, Germany; School of Medicine, University of Roma, Italy, School of Pharmacy, University of Minnesota, Italy. Prof. Badria participated as invited speaker/and or organizer in international conferences in well known research institutes in Switzerland, Malysia, Indone-sia Italy, Cuba, Tunisia, Iran, Germany, Senegal, India, Chile, Romania, USA, Canada, Mexico, and other countries.

View profile

Book chapters authored 1

Books edited 4

Introducing your Author Service Manager

Ms. Katarina Pausic

Ask a question

Book will be abstracted and indexed in